SuperworthXtant Medical profit margin XTNT
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- −10.2%
- Operating margin, 12 months
- −9.6%
- Net margin on a year earlier
- −6.6 pts
- Peer median
- 8.4%
Over the twelve months to Jun 30, 2026, Xtant Medical kept −10.2% of its revenue as net profit, with an operating margin of −9.6% and a gross margin of 59.4%.
Five years earlier its net margin was −5.1%.
The median for 7 medical instruments and supplies stocks of a similar size is 8.4%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 3.7% | 5.4% | 62.9% |
| FY2024 | −14.0% | −10.3% | 58.2% |
| FY2023 | 0.7% | −11.1% | 60.8% |
| FY2022 | −14.6% | −11.7% | 55.4% |
| FY2021 | −8.8% | −7.0% | 58.8% |
| FY2020 | −13.2% | −1.4% | 64.5% |
| FY2019 | −12.7% | −3.5% | 65.8% |
| FY2018 | −97.1% | −83.2% | 60.2% |
| FY2017 | −63.4% | −45.8% | 60.6% |
| FY2016 | −21.7% | −8.4% | 69.2% |
| FY2015 | −3.7% | −20.4% | 65.9% |
| FY2014 | −29.7% | −17.7% | 63.1% |
| FY2013 | −38.4% | −27.2% | 57.1% |
| FY2012 | −23.4% | −15.0% | 68.7% |
| FY2011 | −10.0% | −21.4% | 69.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −10.2% | −6.6 pts | −9.6% | |
| Q1 FY26 | 1.5% | +11.3 pts | 2.7% | |
| Q4 FY25 | 3.7% | +17.7 pts | 5.4% | |
| Q3 FY25 | 1.3% | +16.8 pts | 4.8% | |
| Q2 FY25 | −3.6% | −0.6 pts | 0.0% | |
| Q1 FY25 | −9.8% | −8.2 pts | −6.2% | |
| Q4 FY24 | −14.0% | −14.8 pts | −10.3% | |
| Q3 FY24 | −15.4% | −19.0 pts | −12.3% | |
| Q2 FY24 | −3.0% | +10.0 pts | −12.3% | |
| Q1 FY24 | −1.6% | +11.6 pts | −11.9% | |
| Q4 FY23 | 0.7% | +15.4 pts | −11.1% | |
| Q3 FY23 | 3.5% | +18.6 pts | −10.3% |
Against its peers
Companies in Medical - Instruments & Supplies nearest Xtant Medical's size, closest first, today.
| Company | Profit margin |
|---|---|
| XTNTXtant Medical | −10.2% |
| NEPHNephros | 8.4% |
| APTAlpha Pro Tech | 6.8% |
| KEQUKewaunee Scientific | 3.0% |
| PDEXPro DEX | 17.6% |
| UTMDUtah Medical Products | 29.0% |
| INFUInfuSystem | 6.0% |
| EMBCEmbecta | 8.6% |
| Peer median | 8.4% |
Where Xtant Medical ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Xtant Medical
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.